Penumbra (PEN) vs Insulet (PODD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Penumbra (PEN) has outperformed Insulet (PODD) over the past year, gaining 27.0% versus a loss of 57.1%. Over five years, PEN leads with a +18.2% price change compared with -55.3% for PODD. Penumbra is the larger company by market cap ($12.46 billion vs $9.32 billion), about 1.3 times the size, while Insulet is growing revenue faster (+30.7% vs +17.5%).
On valuation, Insulet trades at a lower forward P/E (17.4x vs 51.6x for Penumbra). Penumbra converts more of its revenue into profit, with a net margin of 12.7% versus 9.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEN | PODD |
|---|---|---|
| Share price | $316.35 | $134.36 |
| Market cap | $12.46B | $9.32B |
| 1-day change | -0.22% | -0.27% |
| YTD return | +1.75% | -52.73% |
| 1-year return | +27.03% | -57.14% |
| 5-year return | +18.15% | -55.29% |
| P/E ratio (TTM) | 77.92 | 25.21 |
| Forward P/E | 51.59 | 17.38 |
| EPS (TTM) | $4.06 | $5.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | $2.71B |
| Revenue growth (YoY) | +17.50% | +30.73% |
| Net income (latest FY) | $177.69M | $247.10M |
| Gross margin | 67.14% | 71.63% |
| Operating margin | 13.48% | 17.50% |
| Net margin | 12.66% | 9.12% |
| 52-week high | $362.41 | $354.88 |
| 52-week low | $221.26 | $126.40 |
| Distance from 52-week high | -12.71% | -62.14% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +14.30% | +27.24% |
| Average volume | 343.03K | 1.69M |
| Shares outstanding | 39.39M | 69.35M |
| Employees | 4,700 | 5,400 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PEN has outperformed PODD by 84.2 percentage points over the past year.
- Penumbra trades at a higher earnings multiple (77.9x vs 25.2x trailing P/E).
- Insulet grew revenue faster in its latest fiscal year (+30.73% vs +17.50%).
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
PEN vs PODD FAQ
Which is bigger, Penumbra or Insulet?
Penumbra (PEN) is larger, with a market capitalization of $12.46B compared with $9.32B for Insulet (PODD).
Which stock has performed better over the past year, PEN or PODD?
PEN returned +27.03% over the past 12 months, compared with -57.14% for PODD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PEN or PODD?
PODD has the lower trailing P/E at 25.2, versus 77.9 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Penumbra and Insulet in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.